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ORIGINAL ARTICLE
Targeting the small airways with dry powder adenosine: a challenging concept
Erica van der Wiel*a,b, Anne J. Lexmond*c, Maarten van den Bergea,b, Dirkje S. Postmaa,b, Paul Hagedoornc,
Henderik W. Frijlinkc, Martijn P. Farenhorstd, Anne H. de Boerc and Nick H. T. ten Hackena,b
aDepartment of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands;
bGroningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, the
Netherlands; cDepartment of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, the Netherlands; dLung
Function Department, University Medical Center Groningen, Groningen, the Netherlands
ABSTRACT
Background: Small-particle inhaled corticosteroids (ICS) provide a higher small airway deposition than
large-particle ICS. However, we are still not able to identify asthma patients who will profit most from
small-particle treatment.
Objective: We aimed to identify these patients by selectively challenging the small and large
airways. We hypothesized that the airways could be challenged selectively using small- and large-
particle adenosine, both inhaled at a high and a low flow rate.
Design: In this cross-over study 11 asthma subjects performed four dry powder adenosine tests,
with either small (MMAD 2.7 µm) or large (MMAD 6.0 µm) particles, inhaled once with a low flow
rate (30 l min–1) and once with a high flow rate (60 l min–1). Spirometry and impulse oscillometry
were performed after every bronchoprovocation step. We assumed that FEV1 reflects the large
airways, and FEF25–75%, R5-R20 and X5 reflect the small airways.
Results: The four adenosine tests were not significantly different with respect to the threshold
values of FEV1 (p = 0.12), FEF25–75% (p = 0.37), R5-R20 (p = 0.60) or X5 (p = 0.46). Both small- and
large-particle adenosine induced a response in the small airways in the majority of the tests.
Conclusions: In contrast to our hypothesis, all four adenosine tests provoked a response in the
small airways and we could not identify different large- or small-airway responders. Interestingly,
even the test with large particles and a high flow rate induced a small-airway response, suggest-
ing that selective challenging of the small airways is not necessary. Future studies should
investigate the relation between particle deposition and the site of an airway response.
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Recent studies in asthma suggest that treatment with
small-particle inhaled corticosteroids (ICS) associates
with improved asthma control and less small airway
dysfunction.[1–3] An advantage of small-particle instead
of large-particle inhaled treatment could be a higher total
lung deposition in addition to better deposition in the
small airways.[4,5] Yet, we are currently not able to select
asthma patients with small airway dysfunction, i.e. those
who will probably benefit most from the inhaled small-
particle medication.
Cohen and colleagues tried for the first time to identify
responders and non-responders to treatment with small-
particle inhaled corticosteroids (ICS) using an indirect
bronchoprovocation test with large and small particles of
dissolved adenosine 5ʹ-monophosphate (AMP).[6] They
saw a significant improvement in the 20% fall in FEV1
(PC20) after bronchoprovocation with small-particle
AMP, and not large-particle AMP, after a 4-week treat-
ment with a small-particle ICS. Interpretation of the data
was hampered by the fact that only 60% of the subjects
reached a PC20 with the small-particle AMP test. The low
response rate was partly attributed to the very small mass
median aerodynamic diameter (MMAD) of 1.1 μm,
which is probably too small for effective airway deposi-
tion with a tidal-breathing method. The challenge with
nebulized AMP has a number of other disadvantages, i.e.
it is impossible to dissolve AMP at higher concentrations
than approximately 320 mg ml–1, the particle size distri-
bution and nebulizer output rate are not consistent over
the entire concentration range, and good clinical manu-
facturing of sterile, diluted agents is more complicated
than manufacturing of most dry powder formulations.[7]
Bronchoprovocation with a dry powder formulation
may help to overcome the above-described disadvan-
tages of AMP nebulization.[8]
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In the current pilot study, we aimed to challenge the
small and large airways selectively with dry powder ade-
nosine. For this challenge, we chose the particle size and
inhalationmaneuver used by Usmani and colleagues [4] as
a reference. These authors studied deposition of monodis-
perse albuterol aerosol (geometric SD ≤1.22), a broncho-
dilator instead of a bronchoconstrictor stimulus as we did,
after one single inspiration by two-dimensional scinti-
graphic imaging.[4] They observed a significant improve-
ment of deposition in the small airways when inhaling
smaller particles, i.e. a small airway deposition of 10, 17
and 25% with respect to particles with an MMAD of 6, 3
and 1.5 μm. In addition, a slow inspiratory flow increased
the deposition in the small airways compared to a high
flow rate, showing that small particles inhaled slowly
deposit in the small airways, whereas large particles deposit
more centrally in the larger airways. In addition, only 5%
of the large particles (6 μm) inhaled with a high flow rate
(67l min–1) deposited in the small airways.
We hypothesized that a small-particle slow-inhalation
bronchoprovocation test gives a higher deposition and thus
a higher response in the small airways than a test with large
particles and/or inhalation with a high flow rate (Figure 1).
Methods
Study design
In this cross-over study subjects performed four adeno-
sine bronchoprovocation tests in randomized order. The
study was approved by the Medical Ethics Committee of
the University Medical Center Groningen and all sub-
jects gave written informed consent (NCT01610921).
Based on the results of Usmani and colleagues [4] we
aimed to include at least 10 subjects, expecting that we
could gather enough data to demonstrate the potential of
the principles analyzed in this pilot study.
Subjects with a doctor’s diagnosis of asthma, never
smokers, 18–65 years old were recruited via advertise-
ments. Subjects were steroid naive or stopped steroids
4 weeks before the first visit. Exclusion criteria were a
recent exacerbation (<2 months), upper respiratory
tract infection (<2 weeks), FEV1 < 50% predicted or
<1.2 l, pregnancy, or a diagnosis of another pulmonary
disease. Subjects were characterized during a baseline
visit assessing impulse oscillometry (IOS), spirometry,
body plethysmography and a conventional nebulized
AMP bronchoprovocation test.[9–13] Subjects with a
Figure 1. Hypothetical response patterns with dry powder adenosine. This simplified figure shows the hypothetical response
patterns upon bronchoprovocation with dry powder adenosine in the present study. The first assumption is that there are three
sites of inflammation: isolated large airway inflammation (left picture), both large and small airway inflammation (middle picture),
isolated small airway inflammation (right picture). The second assumption is that airways only obstruct if adenosine particles (green)
are deposited in inflamed airways (red layer). The third assumption is that large airway dysfunction is reflected by FEV1 and R20, and
small airway dysfunction by FEF27–75%, R5-R20 and X5. The fourth assumption is that large (MMAD 6.0 µm) particles, or particles
inhaled with a high flow rate (60–70 l min–1) deposit in the central airways (upper row), whereas small (MMAD 2.7 µm) particles
inhaled with a low flow rate (30–40 l min–1) deposit in the central and peripheral airways (lower row). In this study we had no
information about the site of airway inflammation, nor the site of adenosine deposition. If the above-described assumptions are
correct there are four potential response patterns (Table 5).




























positive AMP response (PC20 ≤ 320 mg ml
–1) on this
baseline visit were included.
All adenosine bronchoprovocation tests were sched-
uled during the same part of the day with an interval
between 2 and 14 days. Patients stayed steroid naive
during the study and had to withhold short-acting
bronchodilators at least 6 hours before each visit. Dry
powder adenosine bronchoprovocation tests were car-
ried out with either small (MMAD 2.7 µm, geometric
SD of 1.5) or large particles (MMAD 6.0 µm, geometric
SD of 1.8). Both tests were performed once with a slow
inhalation (30–40 l min–1) and once with a fast inhala-
tion (60–70 l min–1).
Adenosine test specifications
The flow rate curve was measured and shown on a
computer screen during each inhalation of adenosine
in order to give visual feedback and target the desired
flow rates. Peak and mean (min–max) flow rates were
recorded for every inhalation maneuver. Before starting
the tests, subjects practiced the inhalation maneuver
until a proper inhalation was performed.
The adenosine dry powder bronchoprovocation test
was performed with doubling adenosine doses ranging
from 0.04 to 20 mg. Each dose was provided in a single
blister, except the 20 mg dose, which was provided in
two blisters of 10 mg. After full expiration, subjects
inhaled the adenosine with one deep inspiration with
the required flow rate, and then held their breath for
10 s. The blisters were directly checked upon dose
release and if required, a second inspiration was per-
formed to ensure administration of the full dose. The
test inhaler is related to the Twincer™ has an air classi-
fier dispersion system similar to the Novolizer®.[14,15]
Performance testing results, specifications of the inha-
ler in combination with dry powder adenosine, and the
first clinical pilot in five asthma patients have been
described by Lexmond and colleagues.[8,16]
Adenosine bronchoprovocation took place with a
time interval of 3 min and measurements of IOS at
30 s and FVC at 90 s similar to the nebulized AMP
bronchoprovocation test. Due to safety reasons the
bronchoprovocation test was stopped when the FEV1
fell ≥20% compared to baseline.
Data analysis
A positive response to the bronchoprovocation test was
defined as a 20% fall (PD20) in the FEV1 or FEF25–75% or a
40% increase (PD40) in any of the IOS parameters R20,
R5-R20 or X5. The 40% increase in IOS parameters was
based on previous studies using a threshold of 40%
increase in resistance measured with the forced oscillation
technique or 40% decrease in specific airway conductance
measured with body plethysmography.[9,17,18] FEV1
and R20 were considered as large airway parameters,
FEF25–75%, R5-R20 and X5 as small airway parameters.
The adenosine dose causing a 20% fall (PD20) or 40%
increase (PD40) was calculated with interpolation using
the log-transformed doses. If a 20% fall in the spirometric
parameters or a 40% increase in the IOS parameters was
reached after the first dose (0.04 mg), a PD of 0.02 was
noted. If a 20% fall or 40% increase was not reached after
the highest dose (20 mg), PD20 and PD40 were calculated
by extrapolation with a maximum of 40 mg. If the test
was stopped due to a 20% fall in FEV1, extrapolation of
PD20 for the FEF25–7% or PD40 for the IOS parameters
was only allowed if the calculated provocative dose was
not higher than twice the last given dose, otherwise no
PD20 or PD40 was assigned. PD20 and PD40 values were
not based on outliers and were verified visually.
The Friedman test was used to test for differences
between the four adenosine bronchoprovocation meth-
ods with respect to eliciting a bronchoconstrictive
response in the large and small airways. Linear mixed
effect models were used to estimate the effect of parti-
cle size and inhalation flow rate on PD20 and PD40. In
addition, linear mixed effect models were used to make
pairwise comparisons between the four tests. Analyses
were performed with SPSS version 20.
Results
Characteristics
A total of 26 subjects gave written informed consent and 11
subjects were included in the study. Fifteen subjects were
excluded due to either a severe (PC20 < 0.04mgml
–1) or no
response to nebulized AMP at screening. One of the
included subjects dropped out during the study because
of respiratory complaints. This subject performed only two
large-particle adenosine tests. All obtained data have been
used in the analyses. Baseline characteristics are shown in
Table 1.
Adenosine dry powder tests
All four different adenosine dry powder tests were
well tolerated by all subjects. A full dose release
required a second inhalation for only 10% of the
blisters. The technical test results with flow rate,
inspiratory volume, and dose release are shown in
Table 2.




























Differences in PD20 and PD40 threshold values
between the four adenosine tests
No significant differences were found between the four
tests for the PD20FEV1 (p = 0.12), P20FEF25–75% (p
= 0.37), PD40R5-R20 (p = 0.60) and PD40X5 (p = 0.46)
(Table 3 Figure 2). Pairwise comparison showed a few
differences between the tests, e.g. the small-particle
slow-inhalation test induced a higher PD20FEV1 than
the other three tests (p μ0.05).
We had hypothesized that small particles inhaled with
a low flow rate would induce an increased response of the
small airways. Analyses using a linear mixed effect model
showed that only inspiratory flow rate had a significant
effect on the response in R5-R20, i.e. a slow inhalation
induced a lower PD40R5-R20 (Estimate -1.61, p=0.04).
No other significant effect of particle size of inspiratory
flow was found.
Large and small airway response to adenosine tests
The large and small airway response to the four adenosine
tests are illustrated in Figure 3, showing one subject as
typical example. The small-particle slow-inhalation test
induced in the majority of the subjects responses in the
parameters FEV1, FEF25–75%, R5-R20 and X5 (Table 4). A
response in R20 was present in only 11 out of all 42 tests.
As a result, PD40R20 was not included in further analyses.
Noteworthy is the high response rate with small airway
Table 1. Characteristics of study population (n = 11).
Median (IQrange)
Age (years) 22 (20;40)
Gender (n, female) 7
ICS use (n, yes) * 10
ICS dose (µg)# 500 (0;1500)
FEV1 (%pred) 92 (86;113)
FEV1/FVC (%) 76 (65;97)
FEF25–75% (%pred) 62 (49;120)
RV (%pred) 92 (35;131)
R20 (kPa l–1 s–1) 0.37 (0.27;0.50)
R5-R20 (kPa l–1 s–1) 0.04 (−0.02;0.32)
X5 (kPa l–1 s–1) −0.1 (−0.25;-0.05)
AX (kPa l–1) 0.23 (0.07;2.73)
PC20 AMP (mg ml
–1) 15.3 (1.51;34.8)
*Four weeks before start of the study; #beclomethasone equivalent.
AMP: adenosine 5ʹ-monophosphate, AX: reactance area, FEF25–75%: forced
expiratory flow between 25% and 75% of FVC, FEV1: forced expiratory
volume in 1 sec, FVC: forced vital capacity, ICS: inhaled corticosteroids,
R5-R20: difference between the resistance of the respiratory system at
5 Hz and 20 Hz, R20: resistance of the respiratory system at 20 Hz, RV:
residual volume, PC20: provocative concentration causing a 20% fall in
FEV1, X5: reactance at 5 Hz.
Table 2. Technical results of adenosine dry powder test.
A. Peak and mean flow rates, and total volume attained per test
Test specification Peak inspiratory flow rate Mean inspiratory flow rate Total inspiratory volume
Particle size (µm) Inhalation flow (l min–1) (l min–1) (min to max) (l min–1) (min to max) (l) (min to max)
2.7 30–40 39.8 (35.1–46.4) 33.0 (28.9–40.4) 2.59 (0.70–4.95)
6.0 60–70 64.5 (60.3–72.1) 49.6 (41.3–53.3) 2.81 (0.57–5.03)
2.7 30–40 40.1 (35.1–46.1) 32.9 (29.1–38.6) 2.86 (0.60–5.52)
6.0 60–70 62.8 (57.0–70.9) 48.6 (44.2–52.3) 2.74 (0.72–3.95)
B. Number of incomplete adenosine dry powder releases after one inhalation per adenosine test
Test specification
Particle size (µm) Inhalation flow (l min–1) Number of provocation steps 2nd inhalation required 3rd inhalation required
2.7 30–40 82 9 0
6.0 60–70 73 6 0
2.7 30–40 94 17 5
6.0 60–70 90 1 0
All patients were able to hold breath for 10 s
Figure 2. Box plots (25–75 percentile with range) of threshold values with differences between the four bronchoprovocation tests.
PD20FEV1: adenosine dose causing a 20% fall in FEV1, PD40R5-R20: adenosine dose causing a 40% increase in R5-R20.




























parameters induced by the large-particle tests, i.e. 8–10
out of 11 subjects.
We had hypothesized that the four different adenosine
tests would elicit the site of airway inflammation based on
different response patterns, i.e. a response in the large
airways only, in the small airways only, in the large and
small airways, or no response in the large and small air-
ways (Figure 1). However, none of the subjects showed a
response exclusively of the large airways (Table 5).
Discussion
This study shows that the adenosine dry powder chal-
lenge can provoke large and small airway constrictive
responses in subjects with asthma. However, in contrast
to our hypothesis we could not demonstrate that our
small-particle slow-inhalation test provoked amore pro-
nounced response in the small airways than the three
other tests. Interestingly, all four dry powder adenosine
tests, even the one with large particles at a fast inhalation,
provoked a response in the small airways.
This is the first study showing that a bronchoprovo-
cation test with a dry powder agent is able to induce a
significant response in the large and small airways in
subjects with asthma. With respect to the response rate
this dry powder adenosine test is an improvement to the
small- and large-particle nebulized AMP test used by
Cohen and colleagues.[6] The use of an inhaler with an
air classifier dispersion system is also totally new and
enabled administration of a consistent aerosol in terms
of particle size distribution over the total dose range.
We expected to observe a pronounced small and
large airway response with the small-particle slow-
inhalation test and a predominantly large airway
response with the other combinations (Figure 1).
However, almost every subject in our study demon-
strated a response in both the large and small airways,
independent of particle size and inhalation flow rate.
How can we explain these unexpected results? First, it
Figure 3. Typical example of large and small airway response per test.











k 2.49 4.62k 3.40k 0.12
Small airways
PD20FEF25–75% (mg)* 1.29 1.30 3.15 1.72 0.37
PD40R5-R20 (mg)* 0.83 0.68 0.15 0.98 0.60
PD40X5 (mg)* 0.74 0.82 2.59 0.84 0.46
*Values were log2 transformed. Median #p-value of Friedman test. Pairwise comparison of the four adenosine tests, results of linear mixed effect model.
ksignificant different from small-particle fast-inhalation test (p < 0.05).
PD20FEV1: adenosine dose causing a 20% fall in FEV1, PD20FEF25–75%: adenosine dose causing a 20% fall in FEF25–75%, PD40R5-R20: adenosine dose causing a
40% increase in R5-R20, PD40X5: adenosine dose causing a 40% increase in X5. Median of PD40R20 are not shown, due to the small sample size.




























may be that we did not achieve the expected selective
deposition of large particles in the large airways and
small particles in the small airways. As we did not
perform an imaging study with radio-labeled adeno-
sine particles, we relied on the findings of Usmani
and colleagues showing the differential deposition
patterns of salbutamol.[4] We realize that the aerody-
namic properties of adenosine may differ from salbu-
tamol. Furthermore, the dry powder adenosine was
not monodisperse even though the delivered adeno-
sine aerosols had a relatively narrow size distribution.
Possibly the use of monodisperse particles with a
smaller diameter would have been more discriminat-
ing. A second explanation may be that the lung func-
tion tests used in this study have had limited
specificity to discriminate between responses in the
large and small airways. It has already been suggested
that FEF25–75% values not only reflect small airway
dysfunction but also partly reflect large airway dys-
function.[19] With regard to IOS, we could not per-
form analyses with the R20, because this parameter
demonstrated a response in only 26% of all tests,
probably reflecting the poor ability of the cartilagi-
nous central airways to narrow. Another explanation
may be that deposition of adenosine in the large air-
ways not only leads to obstruction in the large airways
but also in the small airways. The small airways may
also respond to inflammatory mediators transported
distally via superficial capillary vessels, or to stimula-
tion of sensory nerves with excitation of cholinergic
reflex pathways. A neural mechanism has not exten-
sively been investigated in human bronchial hyperre-
sponsiveness yet, but this may be worthwhile in
perspective of our findings.[20–22]
An important strength of this study is the use of the
same inhaler in all four tests, in combination with a
controlled inspiratory maneuver. By minimizing the
factors that could affect the deposition of adenosine,
we have been able to attribute our observations during
the four tests to particle size and flow rate. A limitation
of the study is that the bronchoprovocations were
stopped based on the fall in FEV1, a large airway para-
meter. The increase in R5-R20, a small airway para-
meter, varied between 40 and 500% for the last given
dose. We chose to stop the test at a 20% fall in FEV1 for
safety reasons, as we had limited experience with dry
powder adenosine, as well as with specifically provoking
the small airways. We used threshold values of a 20% fall
in FEF25–75% and 40% increase in IOS parameters in our
analyses. These are arbitrary cut-off values based on
previous studies, using a threshold of 40% increase in
resistance measured with the forced oscillation techni-
que. We anticipate that a better insight in the small
airway response can be obtained if bronchoprovocation
continues to a predefined dose that is similar for all
subjects. This enables a fair comparison of the tests and
parameters between the subjects. Another limitation of
this study is the small sample size and for this reason we
cannot draw firm conclusions from our results.
To conclude, this study shows that a dry powder
adenosine challenge is an appropriate test to induce
bronchial hyperresponsiveness and can be readily used.
All four dry powder adenosine tests, even the large-
particle fast-inhalation test, provoked a response in the
small airways. In our opinion, the next phase in the
investigation of the small airways should be to elucidate
the exact sites of adenosine deposition and bronchocon-
strictor response, e.g. by using imaging techniques.
Table 5. Response patterns.
Subjects showing a response in the large
and/or small airways
Small particles, slow
inhalation (n = 10)
Small particles, fast
inhalation (n = 10)
Large particles, slow
inhalation (n = 11)
Large particles, fast
inhalation (n = 11)
Only a response in the large* airways 0 0 0 0
Only a response in the small** airways 1 0 2 2
Response in the large* and small** airways 9 10 9 8
No response in the large* or small** airways 0 0 0 1
*Large airway response based on ≥20% decrease in FEV1
**Small airway response based on ≥20% decrease in FEF25–75%, or ≥40% increase in R5-R20 or X5
Table 4. Responses per test.
Percentage of subjects showing a response
per test
Small particles, slow
inhalation (n = 10)
Small particles, fast
inhalation (n = 10)
Large particles, slow
inhalation (n = 11)
Large particles, fast
inhalation (n = 11)
Large airways 20% decrease in FEV1 8 10 9 7
40% increase in R20 2 2 1 3
Small airways 20% decrease in FEF25–75% 9 10 10 9
40% increase in R5-R20 8 7 9 9
40% increase in X5 8 7 9 8
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